Dishman Carbogen Amcis Limited Market Cap ($256.18 Million)
Market Cap & Net Worth: Dishman Carbogen Amcis Limited (DCAL)
Dishman Carbogen Amcis Limited market cap. Dishman Carbogen Amcis Limited (NSE:DCAL) has a market capitalization of $256.18 Million (Rs23.69 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #15286 globally and #768 in its home market, demonstrating a 8.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dishman Carbogen Amcis Limited's stock price Rs151.09 by its total outstanding shares 156783095 (156.78 Million). Also see Dishman Carbogen Amcis Limited (DCAL) cash flow conversion for how efficiently the company converts equity into cash flow.
Dishman Carbogen Amcis Limited Market Cap History (2017–2026)
Dishman Carbogen Amcis Limited market cap history from 2017 to 2026. Data shows change from $550.53 Million to $256.18 Million (-8.84% CAGR). Check Dishman Carbogen Amcis Limited share price for real-time trading data and today's change.
Index Memberships
Dishman Carbogen Amcis Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$142.42 Billion | 0.18% | #153 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.10 Trillion | 0.01% | #536 of 750 |
Weight: Dishman Carbogen Amcis Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dishman Carbogen Amcis Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dishman Carbogen Amcis Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Dishman Carbogen Amcis Limited to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Dishman Carbogen Amcis Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.96x
Dishman Carbogen Amcis Limited's market cap is 12.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $550.53 Million | $17.14 Billion | $1.45 Billion | 0.03x | 0.38x |
| 2018 | $390.47 Million | $16.53 Billion | $1.55 Billion | 0.02x | 0.25x |
| 2019 | $143.10 Million | $19.20 Billion | $2.10 Billion | 0.01x | 0.07x |
| 2020 | $235.34 Million | $20.44 Billion | $1.59 Billion | 0.01x | 0.15x |
| 2021 | $340.98 Million | $19.12 Billion | -$1.65 Billion | 0.02x | N/A |
| 2022 | $160.91 Million | $21.41 Billion | $180.10 Million | 0.01x | 0.89x |
| 2023 | $289.85 Million | $23.15 Billion | -$298.00 Million | 0.01x | N/A |
| 2024 | $458.61 Million | $26.16 Billion | -$1.53 Billion | 0.02x | N/A |
| 2025 | $419.80 Million | $27.11 Billion | $32.40 Million | 0.02x | 12.96x |
Competitor Companies of DCAL by Market Capitalization
Companies near Dishman Carbogen Amcis Limited in the global market cap rankings as of November 4, 2026. Also see Dishman Carbogen Amcis Limited balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Dishman Carbogen Amcis Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Dishman Carbogen Amcis Limited (2017–2026)
Market capitalization of Dishman Carbogen Amcis Limited from 2017 to today. Between 2017 and today, Dishman Carbogen Amcis Limited's market cap moved from $550.53 Million to $ 256.18 Million, with a yearly change of -8.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs256.18 Million | -38.98% |
| 2025 | Rs419.80 Million | -8.46% |
| 2024 | Rs458.61 Million | +58.22% |
| 2023 | Rs289.85 Million | +80.14% |
| 2022 | Rs160.91 Million | -52.81% |
| 2021 | Rs340.98 Million | +44.88% |
| 2020 | Rs235.34 Million | +64.45% |
| 2019 | Rs143.10 Million | -63.35% |
| 2018 | Rs390.47 Million | -29.07% |
| 2017 | Rs550.53 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Dishman Carbogen Amcis Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $256.18 Million USD |
| MoneyControl | $256.18 Million USD |
| MarketWatch | $256.18 Million USD |
| marketcap.company | $256.18 Million USD |
| Reuters | $256.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more